心脏术后非维生素K口服抗凝药使用快速增加
基于多中心胸外科医师学会数据库2011-2018年34188例生物瓣主动脉瓣置换、生物瓣二尖瓣置换或孤立冠状动脉旁路移植患者,18%出院时接受抗凝,其中23%使用非维生素K口服抗凝药。抗凝患者中非维生素K口服抗凝药使用从10.3%增至35.4%(P<.01),各术式均呈增长趋势。调整后30天死亡率(OR 1.94,P=.12)和再手术(OR 0.79,P=.34)与抗凝药选择无关,非维生素K口服抗凝药使用与术后住院时间缩短0.9天相关(P<.01)。
要点
- 心脏术后抗凝患者中非维生素K口服抗凝药使用从10.3%快速增至35.4%。
- 各术式及术后房颤患者中非维生素K口服抗凝药使用均显著增加。
- 短期结局支持其安全性,且与术后住院时间缩短0.9天相关。
核心结论
- 心脏术后非维生素K口服抗凝药使用自2011年以来急剧增加,且不受抗凝指征影响。
- 短期结局支持其在心脏外科场景中的安全性,并与术后住院时间缩短相关。
- 仍需长期研究评估心脏术后非维生素K口服抗凝药的疗效。
研究设计与样本
- 多中心区域胸外科医师学会数据库回顾性分析,纳入2011-2018年生物瓣主动脉瓣置换、生物瓣二尖瓣置换或孤立冠状动脉旁路移植患者。
- 共34188例患者,按抗凝药类型(非维生素K口服抗凝药 vs 维生素K拮抗剂)和时代(早期2011-2014 vs 当代2015-2018)分层。
主要发现
- 34188例中18%(6063例)出院时接受抗凝,其中23%处方非维生素K口服抗凝药。
- 抗凝患者中非维生素K口服抗凝药使用从10.3%增至35.4%(P<.01)。
- 各术式年增长率:冠状动脉旁路移植0.86%/年,生物瓣主动脉瓣置换2.15%/年,生物瓣二尖瓣置换2.72%/年(均P<.01)。
- 术后房颤抗凝患者中,生物瓣置换后非维生素K口服抗凝药使用从6.3%增至35.4%,孤立冠状动脉旁路移植后从12.3%增至40.3%(均P<.01)。
- 调整后30天死亡率(OR 1.94,P=.12)和再手术(OR 0.79,P=.34)与抗凝药选择无关,非维生素K口服抗凝药使用与术后住院时间缩短0.9天相关(P<.01)。
临床怎么用
- 心脏术后需抗凝患者中非维生素K口服抗凝药使用日益普遍,短期安全性数据支持其应用。
- 非维生素K口服抗凝药可能与术后住院时间缩短相关,但需结合患者个体情况选择。
局限性
- 长期疗效数据仍缺乏,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The prevalence of non-vitamin K oral anticoagulant use after cardiac surgery is unknown, particularly in patients with bioprosthetic valves. We sought to define the contemporary use and short-term safety of non-vitamin K oral anticoagulants after cardiac surgery. METHODS: All patients undergoing bioprosthetic aortic valve replacement, bioprosthetic mitral valve replacement, or isolated coronary artery bypass grafting (2011-2018) were evaluated from a multicenter, regional Society of Thoracic Surgeons database. Patients were stratified by anticoagulant type (non-vitamin K oral anticoagulant vs vitamin K antagonist) and era (early [2011-2014] vs contemporary [2015-2018]). RESULTS: Of 34,188 patients, 18% (6063) were discharged on anticoagulation, of whom 23% were prescribed non-vitamin K oral anticoagulants. Among those receiving anticoagulation, non-vitamin K oral anticoagulant use has significantly increased from 10.3% to 35.4% in contemporary practice (P < .01). This trend was observed for each operation type (coronary artery bypass grafting 0.86%/year, bioprosthetic aortic valve replacement: 2.15%/year, bioprosthetic mitral valve replacement: 2.72%/year, all P < .01). In patients with postoperative atrial fibrillation receiving anticoagulation, non-vitamin K oral anticoagulant use has increased from 6.3% to 35.4% and 12.3% to 40.3% after bioprosthetic valve replacement and isolated coronary artery bypass grafting, respectively (both P < .01). In patients receiving anticoagulation at discharge, adjusted 30-day mortality (odds ratio, 1.94; P = .12) and reoperation (odds ratio, 0.79; P = .34) rates were not associated with anticoagulant choice, whereas non-vitamin K oral anticoagulant use was associated with an adjusted 0.9-day decrease (P < .01) in postoperative length of stay. CONCLUSIONS: Non-vitamin K oral anticoagulant use after cardiac surgery has dramatically increased since 2011. This trend is consistent regardless of indication for anticoagulation including bioprosthetic valves. Short-term outcomes support their safety in the cardiac surgery setting with shorter postoperative hospital stays. Long-term studies on the efficacy of non-vitamin K oral anticoagulants after cardiac surgery are still necessary.
引用
- Beller JP, Krebs ED, Hawkins RB, et al. Non-vitamin K oral anticoagulant use after cardiac surgery is rapidly increasing. J Thorac Cardiovasc Surg. 2019. PMID: 31706560. doi:10.1016/j.jtcvs.2019.09.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。